This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.30% per year. These returns cover a period from January 1, 1988 through December 30, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
Visit performance for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Analyst Blog: Archive
Better Quantum Computing Stock: Alphabet at $2.4T or Rigetti at $2.8B?
by Tirthankar Chakraborty
Alphabet is a stronger quantum computing stock compared to Rigetti due to its funding and fundamentals.
GOOGL RGTI
Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Earnings?
by Zacks Equity Research
JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Tremfya. It remains to be seen if MedTech sales improved.
JNJ AMGN ITCI KVUE
Chewy Stock Trading at a Premium: Is the Best Buying Window Over?
by Sumit Singh
Chewy is well-positioned to capitalize on favorable dynamics and internal initiatives. However, rising costs and increased competition remain concerns.
CENT WOOF CHWY BARK
DOW Trading Cheaper Than Industry: Should You Buy the Stock?
by Anindya Barman
While DOW benefits from investment in high-return projects and cost actions, weak end-market demand and declining estimates cast a pall on its prospects.
DOW BASFY EMN LYB
Should Investors Steer Clear of SLB Stock Despite Strong Q4 Earnings?
by Nilanjan Banerjee
SLB reports strong Q4 earnings, but with clients becoming cautious in their discretionary spending, demand for its products & services is likely to be hurt.
SLB HAL BKR
Incyte Gains 15.3% in a Year: Is There Room for Further Growth?
by Zacks Equity Research
INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe there is room for further growth at current levels.
GSK NVS INCY
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
by Zacks Equity Research
The FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs chemotherapy in certain breast cancer patients.
AZN CTMX CSTL ERAS
Can Gilead Sciences Sustain Its Growth Momentum in 2025?
by Ekta Bagri
GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results. While the fundamentals look solid, we advise investors to remain on the sidelines at current levels.
GSK MRK GILD
5 Stocks to Buy as Retail Sector Stages Roaring Recovery
by Ritujay Ghosh
Stocks like AMZN, WMT, URBN, COST and DECK are likely to benefit from the jump in retail sales.
AMZN WMT DECK COST URBN
Travelers to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Better performances across all three segments are likely to aid TRV's fourth-quarter results.
TRV WRB RNR SIGI
GigaCloud Stock Declines 24% in 3 Months: A Buying Opportunity?
by Shuvra Shankar Dey
Here, we present some insights into GCT's recent performance, market trends, and potential trajectory and discuss whether the stock is worth investing in.
RVLV GCT BYON
Fair Isaac Jumps 47% in a Year: How Should You Play the Stock?
by Zacks Equity Research
FICO drives innovation with strong platform growth, but competitive pressures could challenge client acquisition and retention.
IBM ADBE EXPGY FICO
Citigroup Posts Q4 Results: How Should You Approach the Stock Now?
by Riya Anand
C's business-restructuring efforts, along with the Fed rate cuts, look encouraging. Let us delve into other factors to analyze how to approach the C stock.
BAC WFC C
Knight-Swift to Report Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
KNX's fourth-quarter 2024 performance is expected to have been weighed down by high costs related to driver wages, equipment, maintenance, fuel, and other expenses.
LUV CHRW KNX
Here's Why OUTFRONT Media Stock is an Apt Portfolio Pick Now
by Zacks Equity Research
OUT's diversified portfolio of advertising sites, digital billboard conversions and strategic expansions augur well for long-term growth.
CUZ OUT WELL
RGTI Surges 679% in 3 Months: More Room to Grow or Time to Sell?
by Nilanshi Mukherjee
RGTI benefits from an expanding clientele and a strong foothold in the quantum computing space despite quantum market challenges.
AMZN MSFT RGTI QBTS
Will Healthy Revenue Growth Boost Ericsson's Q4 Earnings Results?
by Zacks Equity Research
ERIC is expected to record a top-line expansion year over year in the fourth quarter of 2024, driven by healthy demand across several sectors and portfolio strength.
ADP ERIC IDCC META
Higher Expenses, Weak Asset Quality to Hurt Comerica's Q4 Earnings
by Zacks Equity Research
CMA's fourth-quarter 2024 performance is likely to have been hurt by rising expenses and deteriorating asset quality.
CMA ZION HTH
Airbnb Falls 5% in a Year: Should You Buy, Sell or Hold the Stock?
by Zacks Equity Research
Airbnb faces rising competition, margin compression and regulatory challenges, which raise short-term concerns that could keep investors cautious.
EXPE MMYT BKNG ABNB
UUUU Falls 28% in a Year: Should You Buy, Hold or Sell the Stock?
by Madhurima Das
The decreases in Energy Fuels' stock price and uranium prices have left investors confused about whether to buy the dip or wait for better clarity. Let us analyze.
CCJ DNN UUUU LEU
Is Zumiez Stock a Buy, Hold or Sell Post Holiday Sales Results?
by Zacks Equity Research
Zumiez's expansion of private-label products, new brands and focus on cost efficiency position it for growth despite recent challenges.
ZUMZ ANF DECK GAP
Carpenter Technology Stock Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
CRS gains from strong market demand, cost-cutting initiatives and efforts to preserve liquidity.
CRS FSM ICL MAG
Gap Trades at Low P/E Multiple: Is it the Right Time to Buy the Stock?
by Rajani Lohia
GAP's brand strength, digital innovation and growth initiatives make it a top pick in retail. Strong fundamentals and undervaluation offer great investment potential.
ANF DECK BOOT GAP
AmEx Up 69% in Past Year: More Growth on the Horizon?
by Zacks Equity Research
AXP remains well-poised for growth on strong revenue growth, acquisitions and partnerships as well as a solid cash balance.
AXP EGBN BHLB FMAO
Energy Turns From Laggard to Leader: 5 Stock Winners
by Sweta Killa
The energy sector is leading in the initial weeks of 2025 after lagging over the past two years.
CEG PAA LNG BRY KGEI